대상포진 백신 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of Shingles Vaccines Market

The global Shingles Vaccines Market demonstrated strong expansion in the base year 2025, driven by rising disease prevalence, increasing geriatric population, and growing awareness regarding preventive adult immunization. According to the report, the market size was valued at USD 5.67 billion in 2025. With continued uptake of advanced vaccines and broader immunization coverage, the market is projected to grow to USD 5.95 billion in 2026 and further expand to USD 12.92 billion by 2034. North America dominated the global landscape with a 36.98% market share in 2025, supported by high awareness levels, strong healthcare infrastructure, and widespread adoption of recombinant shingles vaccines.

Shingles vaccines are used to prevent herpes zoster, a painful and often debilitating condition caused by reactivation of the varicella-zoster virus. The virus remains dormant after an individual recovers from chickenpox and can reactivate later in life, particularly among older adults and immunocompromised populations. Vaccination, administered in a two-dose schedule, remains the only effective preventive measure against shingles and its complications.

Market Dynamics

Market Drivers

The rising incidence of shingles globally is a primary factor driving market growth across 2025 and 2026. Aging populations and immunosenescence significantly increase susceptibility to shingles, resulting in higher vaccine demand. Data published in September 2023 indicated a shingles prevalence rate of 1.2-3.4 cases per 1,000 persons per year among younger healthy adults, with substantially higher rates in older populations. In parallel, increasing awareness campaigns and recommendations from health authorities further boost vaccine adoption.

Market Restraints

Side effects associated with shingles vaccines remain a limiting factor. Adverse reactions such as injection-site pain, fatigue, fever, and rare neurological conditions can affect patient confidence. In 2023, Canada discontinued Zostavax due to safety concerns, highlighting how tolerability issues can influence market dynamics and shift demand toward safer alternatives.

Market Opportunities

Addressing cost barriers represents a major growth opportunity. High vaccine prices and limited insurance coverage restrict uptake in several regions. In February 2025, the cost of two doses of SHINGRIX in India ranged between USD 300-400, limiting accessibility. Price reductions, government subsidies, and reimbursement expansion could significantly improve adoption rates and support market growth toward 2034.

Market Challenges

Limited awareness and restricted access in certain regions challenge market expansion. Studies published in October 2023 showed that while 57.2% of participants were aware of the shingles vaccine in selected populations, only 7.7% had received it. Such gaps in awareness and access continue to hinder optimal vaccine coverage.

Shingles Vaccines Market Trends

A key trend shaping the global market is the increasing adoption of recombinant subunit vaccines. Non-live vaccines such as SHINGRIX are preferred due to their superior efficacy and safety profile, particularly for older and immunocompromised individuals. In July 2024, clinical data confirmed that recombinant vaccines not only prevent shingles but also significantly reduce the risk of postherpetic neuralgia, reinforcing their growing dominance.

Segmentation Analysis

By Type

The recombinant/conjugate/subunit segment dominated the market in 2024 and is expected to register the fastest growth through 2034. These vaccines offer high protection without the risks associated with live attenuated formulations. The "others" segment, including mRNA-based vaccines, is gaining attention, with multiple candidates entering clinical trials.

By Product

The SHINGRIX segment held the largest market share in 2024, supported by strong clinical efficacy. Data published in July 2024 showed SHINGRIX to be 97% effective in preventing shingles among adults aged 50-69 years, reinforcing its leadership position. Pipeline products, including mRNA-based vaccines, form the remainder of the segment.

By Distribution Channel

Government suppliers dominated the market in 2024, driven by national immunization initiatives and favorable reimbursement policies. Hospital and retail pharmacies are expected to maintain significant shares due to increasing public-private partnerships and improved access in urban healthcare settings.

Regional Outlook

North America

North America generated USD 2.10 billion in 2025 and USD 2.16 billion in 2026, driven by high disease prevalence and strong vaccination programs. The U.S. leads the region, with approximately 1 million shingles cases annually, supporting sustained vaccine demand.

Europe

Europe holds the second-largest share, supported by favorable reimbursement frameworks and region-wide awareness initiatives. Collaborative campaigns have strengthened adult vaccination coverage across EU countries.

Asia Pacific

Asia Pacific is the fastest-growing region, supported by rising elderly populations, increasing disposable income, and expanding government-backed immunization efforts. Awareness campaigns by leading manufacturers further support growth.

Latin America and Middle East & Africa

These regions are expected to witness steady growth, driven by improving healthcare access, rising awareness, and gradual introduction of advanced shingles vaccines.

Competitive Landscape

The market is led by GSK plc. and Pfizer Inc., which together account for a significant share. GSK's SHINGRIX remains the most widely adopted product globally, supported by regulatory approvals and awareness initiatives. Pfizer, in collaboration with BioNTech, is advancing mRNA-based shingles vaccines. Other notable players include Moderna Inc., Dynavax Technologies, Jiangsu Recbio Technology Co., Ltd., and Curevo Inc., all actively investing in next-generation vaccine development.

Report Coverage

The shingles vaccines market report provides a comprehensive analysis aligned strictly with 2025, 2026, and 2034 market values. It covers market dynamics, segmentation by type, product, and distribution channel, regional performance, competitive landscape, and key industry developments, offering a detailed view of market evolution across the forecast period.

Conclusion

The global Shingles Vaccines Market exhibits a strong and well-supported growth outlook across the report years, driven by rising shingles incidence, demographic aging, and increasing emphasis on adult preventive immunization. Valued at USD 5.67 billion in 2025, the market reflects growing acceptance of vaccination as the most effective preventive strategy against herpes zoster and its long-term complications. The steady rise to USD 5.95 billion in 2026 highlights continued short-term expansion supported by awareness initiatives, strong government participation, and high adoption of recombinant subunit vaccines, particularly in North America, which accounted for 36.98% of the global market in 2025.

Looking ahead, the projected expansion to USD 12.92 billion by 2034 is underpinned by sustained demand from aging populations, technological advancements in non-live vaccine platforms, and pipeline developments such as mRNA-based shingles vaccines. While challenges related to cost barriers, side effects, and uneven awareness persist across certain regions, increasing government support, reimbursement policies, and public-private collaborations are expected to enhance accessibility and uptake. Overall, the shingles vaccines market is positioned for consistent long-term value growth, maintaining its critical role in adult immunization and preventive healthcare throughout the forecast period.

Segmentation

By Type

• Recombinant/Conjugate/Subunit
• Others

By Product

• SHINGRIX
• Others

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Region

• North America (By Type, Product, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Product, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Product, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • o
  • Rest of Asia Pacific
• Latin America (By Type, Product, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Product, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Epidemiology of Shingles (Herpes Zoster)
• 4.2. Reimbursement Scenario, By Key Countries/Regions
• 4.3. Pipeline Analysis, By Key Players
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Recombinant/Conjugate/Subunit
  • 5.1.2. Others
• 5.2. Market Analysis, Insights and Forecast - Product
  • 5.2.1. SHINGRIX
  • 5.2.2. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital & Retail Pharmacies
  • 5.3.2. Government Suppliers
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Recombinant/Conjugate/Subunit
  • 6.1.2. Others
• 6.2. Market Analysis, Insights and Forecast - Product
  • 6.2.1. SHINGRIX
  • 6.2.2. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital & Retail Pharmacies
  • 6.3.2. Government Suppliers
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Recombinant/Conjugate/Subunit
  • 7.1.2. Others
• 7.2. Market Analysis, Insights and Forecast - Product
  • 7.2.1. SHINGRIX
  • 7.2.2. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital & Retail Pharmacies
  • 7.3.2. Government Suppliers
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Recombinant/Conjugate/Subunit
  • 8.1.2. Others
• 8.2. Market Analysis, Insights and Forecast - Product
  • 8.2.1. SHINGRIX
  • 8.2.2. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital & Retail Pharmacies
  • 8.3.2. Government Suppliers
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Recombinant/Conjugate/Subunit
  • 9.1.2. Others
• 9.2. Market Analysis, Insights and Forecast - Product
  • 9.2.1. SHINGRIX
  • 9.2.2. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital & Retail Pharmacies
  • 9.3.2. Government Suppliers
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Recombinant/Conjugate/Subunit
  • 10.1.2. Others
• 10.2. Market Analysis, Insights and Forecast - Product
  • 10.2.1. SHINGRIX
  • 10.2.2. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital & Retail Pharmacies
  • 10.3.2. Government Suppliers
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Moderna Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Jiangsu Recbio Technology Co., Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Pfizer Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Dynavax Technologies
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Curevo Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)